Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency

Crescent Gbeto (1) , Sylvie Quaranta (2) , Roxane Mari (1) , Raphaelle Fanciullino (3) , Catherine Roche (2) , Sophie Nahon (2) , Caroline Solas (2, 3) , L’houcine Ouafik (4, 5) , Bruno Lacarelle (6, 3) , Thierry Allegre (7) , Joseph Ciccolini (3, 2)

1 CHIAP - Centre Hospitalier d'Aix en Provence [Aix-en-Provence]
2 Laboratoire de Biologie médicale, AP-HM
3 SMARTc - Simulation and Modeling of Adaptive Response for Therapeutics in Cancer
4 Laboratoire de Transfert d'Oncologie Biologique [Hôpital Nord - APHM]
5 INP - Institut de neurophysiopathologie
6 Pharmacocinétique Toxicocinétique - [Hôpital de la Timone - APHM]
7 Service Hématologie et Médecine Interne

Domains: Life Sciences [q-bio]; Cancer

Crescent Gbeto, Sylvie Quaranta, Roxane Mari, Raphaelle Fanciullino, Catherine Roche, et al.. Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency. Pharmacogenomics, 2019, 20 (13), pp.931-938. ⟨10.2217/pgs-2019-0028⟩. ⟨hal-02483216⟩